Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)

Forma Therapeutics, Inc.Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) cohort.

Asset / SponsorPhaseRating
Zimberelimab
University of Texas Southwestern Medical Center
Phase 2CCC
Domvanalimab
University of Texas Southwestern Medical Center
Phase 2CCC
Nivolumab
Forma Therapeutics, Inc.
Phase 1/2CCC
Azacitidine
Forma Therapeutics, Inc.
Phase 1/2CCC
Olutasidenib
Forma Therapeutics, Inc.
Phase 1/2CCC

View all 9 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →